Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10158389 | Clinical Therapeutics | 2018 | 10 Pages |
Abstract
Coadministration of ertugliflozin with rifampin decreased ertugliflozin AUC0-â and Cmax by 39% and 15%, respectively. The effect of the reduced exposure was evaluated using the ertugliflozin dose-response model. The model predicted that a 5-mg ertugliflozin dose after coadministration with rifampin is expected to maintain clinically meaningful glycemic efficacy. Therefore, no dose adjustment of ertugliflozin is recommended when ertugliflozin is coadministered with a UGT and CYP inducer, such as rifampin.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Vikas K. MBA, PhD, Vaishali PhD, Yali MD, MS, Kyle MAS, Haihong MS, MBA, Anne DVM, PhD, Didier MD, Steven G. PharmD, David L. MD, FRCPC,